Regeneron Pharmaceuticals (REGN) Gross Margin (2009 - 2026)
Regeneron Pharmaceuticals' quarterly Gross Margin came in at 91.79% in Q1 2026, down 165.0% year-on-year from 141.22% in Q1 2025, and down 4.83% quarter-over-quarter from 96.45% in Q4 2025.
Regeneron Pharmaceuticals has reported Gross Margin for 18 years, with the latest figure at 91.79% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin fell 165.0% year-over-year to 91.79%; the trailing twelve-month figure through Mar 2026 stood at 93.63% (up 81.0% YoY), and the FY2025 full-year result was 93.31%, up 96.0% from the prior year.
- Gross Margin for Q1 2026 stood at 91.79%, down from 96.45% in the prior quarter.
- The five-year high for Gross Margin was 96.45% in Q4 2025, with the low at 314.6% in Q1 2022.
- Average Gross Margin over 5 years is 55.79%, with a median of 93.44% recorded in 2025.
- Year-over-year, Gross Margin slumped 40736 bps in 2022 and jumped 40672 bps in 2023.
- Tracing REGN's Gross Margin over 5 years: stood at 138.4% in 2022, then surged by 168 bps to 93.88% in 2023, then fell by 3 bps to 91.38% in 2024, then advanced by 6 bps to 96.45% in 2025, then dropped by 5 bps to 91.79% in 2026.
- The last three Gross Margin figures came in at 91.79% (Q1 2026), 96.45% (Q4 2025), and 93.59% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.79% |
| Dec 31, 2025 | 96.45% |
| Sep 30, 2025 | 93.59% |
| Jun 30, 2025 | 92.50% |
| Mar 31, 2025 | 93.44% |
| Dec 31, 2024 | 91.38% |
| Sep 30, 2024 | 92.95% |
| Jun 30, 2024 | 93.73% |
| Mar 31, 2024 | 93.85% |
| Dec 31, 2023 | 93.88% |
| Sep 30, 2023 | 93.70% |
| Jun 30, 2023 | 93.27% |
| Mar 31, 2023 | 92.12% |
| Dec 31, 2022 | -138.40% |
| Sep 30, 2022 | 93.99% |
| Jun 30, 2022 | 94.78% |
| Mar 31, 2022 | -314.60% |
| Dec 31, 2021 | 83.61% |
| Sep 30, 2021 | 93.79% |
| Jun 30, 2021 | 97.00% |
| Mar 31, 2021 | 92.76% |
| Dec 31, 2020 | 98.46% |
| Sep 30, 2020 | 94.29% |
| Jun 30, 2020 | 91.14% |
| Mar 31, 2020 | 95.69% |
| Dec 31, 2019 | 94.18% |
| Sep 30, 2019 | 93.71% |
| Jun 30, 2019 | 94.58% |
| Mar 31, 2019 | 92.63% |
| Dec 31, 2018 | 94.74% |
| Sep 30, 2018 | 95.21% |
| Jun 30, 2018 | 96.54% |
| Mar 31, 2018 | 96.98% |
| Dec 31, 2017 | 96.15% |
| Sep 30, 2017 | 96.15% |
| Jun 30, 2017 | 95.87% |
| Mar 31, 2017 | 95.36% |
| Dec 31, 2016 | 96.37% |
| Sep 30, 2016 | 97.55% |
| Jun 30, 2016 | 96.60% |
| Mar 31, 2016 | 93.43% |
| Dec 31, 2015 | 93.53% |
| Sep 30, 2015 | 94.09% |
| Jun 30, 2015 | 93.91% |
| Mar 31, 2015 | 95.10% |
| Dec 31, 2014 | 95.27% |
| Sep 30, 2014 | 95.36% |
| Jun 30, 2014 | 95.50% |
| Mar 31, 2014 | 95.61% |
| Dec 31, 2013 | 94.35% |
| Sep 30, 2013 | 95.27% |
| Jun 30, 2013 | 94.04% |
| Mar 31, 2013 | 93.63% |
| Dec 31, 2012 | 92.85% |
| Sep 30, 2012 | 95.29% |
| Jun 30, 2012 | 92.82% |
| Mar 31, 2012 | 94.69% |
| Dec 31, 2011 | 97.57% |
| Sep 30, 2011 | 99.56% |
| Jun 30, 2011 | 99.63% |
| Mar 31, 2011 | 99.66% |
| Dec 31, 2010 | 104.59% |
| Sep 30, 2010 | 92.46% |
| Jun 30, 2010 | 99.65% |
| Mar 31, 2010 | 61.98% |
| Dec 31, 2009 | 97.05% |
| Sep 30, 2009 | 99.60% |
| Jun 30, 2009 | 90.33% |